An open-label, multi-center, expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist. [Programma in aperto, multicentrico, di accesso allargato a ranibizumab, in pazienti con diminuzione visiva causata dall`™edema maculare diabetico per i quali non esistano adeguate alternative terapeutiche.]

Trial Profile

An open-label, multi-center, expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist. [Programma in aperto, multicentrico, di accesso allargato a ranibizumab, in pazienti con diminuzione visiva causata dall`™edema maculare diabetico per i quali non esistano adeguate alternative terapeutiche.]

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2014

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema; Vision disorders
  • Focus Adverse reactions
  • Sponsors Novartis Pharma
  • Most Recent Events

    • 28 Jan 2014 Status changed from recruiting to completed as reported by European clinical Trial Database Report.
    • 13 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top